May 05,2021

Nemaura Medical Announces Order for 200,000 sugarBEAT® Sensors

Based on the success of the soft launch in the U.K., the Company is advancing discussions for joint launches in Germany, Saudi Arabia and UAE

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor

Continuous glucose monitoring (CGM) devices are used for evaluating real-time glucose levels to optimize diabetes management. There is limited information, however, on whether readings differ when a device is placed on the right versus the left arm. This study evaluated the mean difference in glucose levels between the right and left arm and the effect of unilateral arm exercise on this difference. The effect of an intermittent fasting diet on body fat percentage was also evaluated.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Nemaura Medical Announces Progress on Listing of sugarBEAT® For Reimbursement in Germany

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced progress with the German regulatory authority (GBA) to achieve reimbursement for its sugarBEAT® device.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
May 06,2021

Algorithms for Automated Insulin Delivery: An Overview

The technology needed to “close the loop,” that is, a system for continuous glucose monitoring and a pump that infuses insulin, are only 2 of the 3 components needed for each system for automated insulin delivery (AID), the other is a “translation” of the glucose information into the appropriate amount of insulin to be applied at a given point in time to keep glucose levels in the body in the target range.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 08,2021

Adverse Event Data for Years 2018 to 2020 for Diabetes Devices

Unlike performance evaluations, which are often conducted under ideal conditions, adverse events occur during actual device use for people with diabetes. This report summarizes the number of adverse events for the years 2018 to 2020 for the 3 diabetes devices: blood glucose meters (BG), continuous glucose monitors (CGM), and insulin pumps.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 10,2021

Use and Accuracy of Inpatient CGM During the COVID-19 Pandemic: An Observational Study of General Medicine and ICU Patients

Continuous glucose monitoring (CGM) is widely used in the outpatient setting for people with diabetes and has been limited to investigational use only for the inpatient population. In April 2020, the US FDA exercised enforcement discretion for the temporary use of inpatient CGM during the pandemic, thus hospitals were presented the opportunity to implement this technology.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 14,2021

One Drop Receives CE Mark for AI-Powered Blood Glucose Forecasts

Powered by nearly 25 billion health data points, One Drop’s CE-marked glucose predictions enable people living with chronic conditions to be proactive about their health

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
May 19,2021

Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles

CeQur Simplicity™ (CeQur, Marlborough, MA) is a 3-day insulin delivery patch designed to meet mealtime insulin requirements. A recently reported 48-week, randomized, multicenter, interventional trial compared efficacy, safety and self-reported outcomes in 278 adults with type 2 diabetes (T2D) on basal insulin therapy who initiated and managed mealtime insulin therapy with a patch pump versus insulin pen. We assessed changes in key glycemic metrics among a subset of patients who wore a continuous glucose monitoring (CGM) device.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 27,2021

The Frequency of Intermittently Scanned Glucose and Diurnal Variation of Glycemic Metrics

The relation between the frequency of intermittently scanned continuous glucose monitoring (isCGM) and diurnal variation of time in range (TIR) and time below range (TBR) is unknown.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 30,2021

A Conditional Generative Adversarial Network for Synthesis of Continuous Glucose Monitoring Signals

This report describes how a Conditional Generative Adversarial Network (CGAN) was used to synthesize realistic continuous glucose monitoring systems (CGM) from healthy individuals and individuals with type 1 diabetes over a range of different HbA1c levels.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM